TREATMENT OF HAEMANGIOENDOTHELIOMAS WITH ALPHA INTERFERON

The Lancet

Volumn 334, Issue 8662, 1989, Pages 565-567

  Orchard, PaulJ ^a   Smith III, ClarkM ^a   Woods, WilliamG ^a   Day, DeborahL ^a   Dehner, LouisP ^a   Shapiro, Ralph ^a  

^a Laboratory Medicine and Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PREDNISONE;

CHILD; HEMANGIOENDOTHELIOMA; HUMAN; INFANT; LETTER; PRIORITY JOURNAL;

CASE REPORT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HEMANGIOENDOTHELIOMA; HUMAN; INFANT; INTERFERON TYPE I; LUNG NEOPLASMS; MALE; PALATAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0024343441     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(89)90694-6     Document Type: Letter

References (8)

1. Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children
2. Laser therapy for selected cutaneous vascular lesions in the pediatric population: a review
3. Kasabach-Merritt syndrome: therapeutic considerations
4. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2A
5. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma
6. The role of interferon in the therapy of epidemic Kaposi's sarcoma
7. Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells